Inhibition of NLRP3 alleviates calcium oxalate crystal-induced renal fibrosis and crystal adhesion
Urolithiasis · 04.03.2025 · 53 (1)
DOI: 10.1007/s00240-025-01716-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urolithiasis, online erschienen am 04.03.2025. Verfasst von Yuexian Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230001, Anhui, China. Hauptthemen laut MEDLINE: Calcium Oxalate, NLR Family, Pyrin Domain-Containing 3 Protein, Kidney Calculi, Kidney. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: the National Natural Science Foundation of China.
Abstract (Originalsprache)
Kidney stones are gaining attention as one of the most common urological diseases. In this study, we first constructed a mouse model of calcium oxalate (CaOx) crystal deposition by intraperitoneal injection of glyoxalate (Gly) and found that the levels of NLRP3, CASP1 and ASC, which constitute the NLRP3 inflammasome, as well as the level of its downstream product, IL-1β, were elevated in the kidneys of the model group of mice, as determined by RNA-seq. We then examined NLRP3 expression via immunohistochemistry, immunofluorescence, qPCR, and Western blotting in human samples, calcium oxalate monohydrate (COM)-stimulated HK2 cells, and a model of calcium oxalate crystal deposition via intraperitoneal injection. We then constructed systemic NLRP3 knockout mice and found via RNA-seq that CaOx crystal-induced renal fibrosis and crystal adhesion may be attenuated after the knockout of NLRP3. We further substantiated these findings by knocking down NLRP3 both in vitro and in NLRP3-knockout mice. Consistently, we observed more pronounced calcium oxalate crystal-induced renal fibrosis and enhanced crystal adhesion upon overexpression of NLRP3 in vitro and in vivo. Ultimately, we utilized the NLRP3 inhibitor MCC950 to support the potential of NLRP3 as a therapeutic target. Our research revealed that NLRP3 plays a pivotal role in kidney stone formation by mitigating renal fibrosis and reducing crystal adhesion induced by CaOx crystals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230001, Anhui, China.
- Institute of Urology, Anhui Medical University, Hefei, 230001, Anhui, China.
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, 230001, Anhui, China.
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230001, Anhui, China. haozongyao@ahmu.edu.cn.
- Institute of Urology, Anhui Medical University, Hefei, 230001, Anhui, China. haozongyao@ahmu.edu.cn.
- Anhui Province Key Laboratory of Urological and Andrological Diseases Research and Medical Transformation, Anhui Medical University, Hefei, 230001, Anhui, China. haozongyao@ahmu.edu.cn.
Förderung
- the National Natural Science Foundation of China
Zitieren
APA
Xu, Y., Li, G., Liu, W., Ge, D., Hao, Z., & Wang, W. (2025). Inhibition of NLRP3 alleviates calcium oxalate crystal-induced renal fibrosis and crystal adhesion. Urolithiasis, 53(1). https://doi.org/10.1007/s00240-025-01716-1
Vancouver
Xu Y, Li G, Liu W, Ge D, Hao Z, Wang W. Inhibition of NLRP3 alleviates calcium oxalate crystal-induced renal fibrosis and crystal adhesion. Urolithiasis. 2025;53(1). doi:10.1007/s00240-025-01716-1
BibTeX
@article{Xu2025,
author = {Xu, Yuexian and Li, Guoxiang and Liu, Wanqing and Ge, Defeng and Hao, Zongyao and Wang, Wei},
title = {Inhibition of NLRP3 alleviates calcium oxalate crystal-induced renal fibrosis and crystal adhesion},
journal = {Urolithiasis},
year = {2025},
volume = {53},
number = {1},
doi = {10.1007/s00240-025-01716-1}
}
EUVIMED